Recently, the vascular endothelial growth factor (VEGF) inhibitor, bevacizumab (BEV) has also emerged as an effective systemic treatment for recurrent GBM, replacing TMZ as the standard of care (13–16). The gene discussed is VEGFA; the disease is glioblastoma.